Download PDF
Endoscopy 2004; 36(2): 103-109
DOI: 10.1055/s-2004-814177
State of the Art Review
© Georg Thieme Verlag Stuttgart · New York

Gastroesophageal Reflux Disease and Barrett’s Esophagus

H.  Koop1
  • 1Dept. of Medicine II/Gastroenterology, Helios Hospital, Buch Hospital (Academic Teaching Hospital of Humboldt University), Berlin, Germany
Further Information

Publication History

Publication Date:
06 February 2004 (online)

Also available at
    Permissions and Reprints

Gastroesophageal reflux disease (GERD) is a very common disorder, mainly occurring in Western countries. The nonerosive form of GERD, which occurs in more than half of the patients affected, deserves particular attention. Administering symptomatic therapy without a prior endoscopic examination has become an attractive option, since it also provides diagnostic information. Proton-pump inhibitors (PPIs) have become established as the standard therapy, but new insights into the pathophysiology of the condition may lead to new treatment options using γ-aminobutyric acid (GABA) agonists. Endoscopic therapy is still at the experimental stage and has yet to prove its value as an alternative to PPI and surgery. However, it is questionable whether antireflux surgery is more cost-effective in the longer term.
Gastroenterologists are now much more aware of Barrett’s esophagus than was the case a few years ago. Barrett’s esophagus is a frequent finding in patients with reflux symptoms, but is a rare cause of death in affected patients. For several reasons, there is a large gap between recommendations regarding surveillance, on the one hand, and everyday practice on the other. New diagnostic procedures such as chromoendoscopy may allow better detection of premalignant and malignant alterations in metaplastic mucosa, but the safety of such techniques has been questioned. Prophylactic ablation is a debatable approach, whereas endoscopic interventions in patients with high-grade dysplasia and early adenocarcinoma are continuing to develop as attractive alternatives to esophagectomy in selected patients. It remains to be seen whether chemoprevention using cyclooxygenase-2 (COX-2) inhibitors should be carried out in high-risk patients with Barrett’s esophagus, in order to prevent malignant transformation to esophageal cancer.

References

  • 1 Spechler S J, Jain S K, Tendler D A, Parker R A. Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease.  Aliment Pharmacol Ther. 2002;  16 1795-1800
    CrossrefPubMedGoogle Scholar
  • 2 Shaker R, Castell D O, Senfeld P S, Spechler S J. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association.  Am J Gastroenterol. 2003;  98 1487-1493
    CrossrefPubMedGoogle Scholar
  • 3 Mathus-Vieen E MH, Tytgat G NJ. Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension.  Scand J Gastroenterol. 2002;  37 1246-1252
    CrossrefPubMedGoogle Scholar
  • 4 Collings K L, Pierce Pratt F, Rodriguez-Stanley S. et al . Esophageal reflux in conditioned runners, cyclists, and weightlifters.  Med Sci Sports Exerc. 2003;  35 730-735
    PubMedGoogle Scholar
  • 5 Cremonini F, di Caro S, Delgado-Aros S. et al . Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease.  Aliment Pharmacol Ther. 2003;  18 279-289
    CrossrefPubMedGoogle Scholar
  • 6 Martinez S D, Malagon I B, Garewal H S. et al . Non-erosive reflux disease (NERD): acid reflux and symptom patterns.  Aliment Pharmacol Ther. 2003;  17 537-545
    PubMedGoogle Scholar
  • 7 Mäntynen T, Färkkilä M, Kunnamo I. et al . The impact of upper GI endoscopy referral volume on the diagnosis of gastroesophageal reflux disease and its complications: 1-year cross sectional study in a referral area with 260,000 inhabitants.  Am J Gastroenterol. 2002;  97 2524-2529
    CrossrefPubMedGoogle Scholar
  • 8 Pandolfino J E, Richter J E, Ours T. et al . Ambulatory esophageal pH monitoring using wireless system.  Am J Gastroenterol. 2003;  98 740-749
    CrossrefPubMedGoogle Scholar
  • 9 Bowrey D J, Williams G T, Clark G W. Histological changes in the oesophageal squamous mucosa: correlation with ambulatory 24 hour pH monitoring.  Clin Pathol. 2003;  56 205-208
    PubMedGoogle Scholar
  • 10 Kawamura M, Ohara S, Koike T. et al . The effects of lansoprazole on erosive oesophagitis are influenced by CYP 2C19 polymorphism.  Aliment Pharmacol Ther. 2003;  17 965-973
    CrossrefPubMedGoogle Scholar
  • 11 Dalby-Payne J R, Morris A M, Craig J C. Meta-analysis of randomized controlled trials on the benefit and risks of using cisapride for the treatment if gastroesophageal reflux in children.  Gastroenterol Hepatol. 2003;  18 196-202
    PubMedGoogle Scholar
  • 12 Ciccaglione A F, Marzio L. Effect of acute and chronic administration of the GABAB agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease.  Gut. 2003;  52 464-470
    CrossrefPubMedGoogle Scholar
  • 13 Vela M F, Tutuian R, Katz P O, Castell D O. Baclofen decreases acid and non-acid post-prandial gastroesophageal reflux measured by combined multichannel intraluminal impedance and pH.  Aliment Pharmacol Ther. 2003;  17 243-251
    CrossrefPubMedGoogle Scholar
  • 14 Cantu P, Carmagnola S, Savojardo D. et al . Effect of non-selective gamma-aminobutyric acid receptor stimulation on motor function of the lower oesophageal sphincter and gastro-oesophageal reflux in healthy human subjects.  Aliment Pharmacol Ther. 2003;  18 699-704
    CrossrefPubMedGoogle Scholar
  • 15 Koeck G H, Sifrim D, Lerut T. et al . Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors.  Gut. 2003;  52 1397-1402
    CrossrefPubMedGoogle Scholar
  • 16 Triadafilopoulos G, DiBase J K, Nostrant T T. et al . The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial.  Gastrointest Endosc. 2002;  55 149-156
    CrossrefPubMedGoogle Scholar
  • 17 Houston H, Khaitan L, Holzman M, Richards W O. First year experience of patients undergoing the Stretta procedure.  Surg Endosc. 2003;  17 401-404
    CrossrefPubMedGoogle Scholar
  • 18 Corley D A, Katz P, Wo J M. et al . Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled study.  Gastroenterology. 2003;  125 668-676
    CrossrefPubMedGoogle Scholar
  • 19 Tam W C, Schoeman M N, Zhang Q. et al . Delivery of radiofrequency energy to the lower oesophageal sphincter and gastric cardia inhibits transient lower oesophageal sphincter relaxations and gastro-oesophageal reflux in patients with reflux disease.  Gut. 2003;  52 479-485
    CrossrefPubMedGoogle Scholar
  • 20 Mahmood Z, McMahon B P, Arfin Q. et al . Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up.  Gut. 2003;  52 34-39
    CrossrefPubMedGoogle Scholar
  • 21 Velanovich V, Ben-Menachem T, Goel S. Case-control comparison of endoscopic gastroplication with laparoscopic fundoplication in the management of gastroesophageal reflux disease: early symptomatic outcome.  Surg Laparosc Endoscop Percut Tech. 2002;  12 219-223
    PubMedGoogle Scholar
  • 22 Johnson D A, Ganz R, Aisenberg J. et al . Endoscopic, deep mural implantation of Enteryx for treatment of GERD: 6-month follow-up of a multicenter trial.  Am J Gastroenterol. 2003;  98 250-258
    CrossrefPubMedGoogle Scholar
  • 23 Cohen J A, Arain A, Harris P A. et al . Surgical trial investigating nocturnal gastroesophageal reflux and sleep (STRINGERS).  Surg Endosc. 2003;  17 394-400
    CrossrefPubMedGoogle Scholar
  • 24 Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic fundoplication in a U.S. community.  Am J Med. 2003;  114 1-5
    CrossrefPubMedGoogle Scholar
  • 25 DiRe C A, Jones M P, Rulyak S J, Kahrilas P J. The economics of laparoscopic Nissen fundoplication.  Clin Gastroenterol Hepatol. 2003;  1 328-332
    CrossrefPubMedGoogle Scholar
  • 26 Hagedorn C, Jonson C, Lonroth H. et al . Efficacy of an anterior as compared with a posterior laparoscopic partial fundoplication: results from a randomized controlled trial.  Ann Surg. 2003;  238 189-196
    CrossrefPubMedGoogle Scholar
  • 27 Crysos E, Tsiaoussis J, Zoras O J. et al . Laparoscopic surgery for gastroesophageal reflux disease with impaired esophageal peristalsis: total or partial fundoplication?.  J Am Coll Surg. 2003;  197 8-15
    CrossrefPubMedGoogle Scholar
  • 28 Jaspersen D, Kulig M, Labenz J. et al . Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD study.  Aliment Pharmacol Ther. 2003;  17 1515-1520
    CrossrefPubMedGoogle Scholar
  • 29 Poe R H, Kallay M C. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment.  Chest. 2003;  123 679-684
    CrossrefPubMedGoogle Scholar
  • 30 Green B T, Broughton W A, O’Connor J B. Marked improvement in nocturnal gastroesophageal reflux in a large cohort of patients with obstructive sleep apnea treated with continuous positive airway pressure.  Arch Intern Med. 2003;  163 41-45
    CrossrefPubMedGoogle Scholar
  • 31 Anderson L A, Murray L J, Murphy S J. et al . Mortality in Barrett’s oesophagus: results from a population based study.  Gut. 2003;  52 1081-1084
    CrossrefPubMedGoogle Scholar
  • 32 Taha A S, Angerson W J, Morran C G. Reflux and Barrett’s oesophagus after gastric surgery: long-term follow-up and implications for the roles of gastric acid and bile in oesophagitis.  Aliment Pharmacol Ther. 2003;  17 547-552
    PubMedGoogle Scholar
  • 33 Kaur B S, Triadafiloloulos G. Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett’s esophagus are COX-2 and PKC-epsilon dependent.  Am J Physiol. 2002;  283 G327-334
    PubMedGoogle Scholar
  • 34 Haigh C R, Attwood S EA, Thompson D G. et al . Gastrin induces proliferation in Barrett’s metaplasia through activation of the CCK2 receptor.  Gastroenterology. 2003;  124 615-625
    CrossrefPubMedGoogle Scholar
  • 35 Doak S H, Jenkins G JS, Parry E M. et al . Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett’s oesophagus.  Gut. 2003;  52 623-628
    CrossrefPubMedGoogle Scholar
  • 36 Fitzgerald R C, Abdala S, Onwuegbusi B A. et al . Inflammatory gradient in Barrett’s oesophagus: implications for disease complications.  Gut. 2002;  51 316-322
    CrossrefPubMedGoogle Scholar
  • 37 Egger K, Werner M, Meining A. et al . Biopsy surveillance is still necessary in patients with Barrett’s oesophagus despite new imaging techniques.  Gut. 2003;  52 18-23
    CrossrefPubMedGoogle Scholar
  • 38 Mandal A, Playford R J, Wicks A C. Current practice in surveillance strategy for patients with Barrett’s oesophagus in the UK.  Aliment Pharmacol Ther. 2003;  17 1319-1324
    CrossrefPubMedGoogle Scholar
  • 39 Inadomi J M, Sampliner R, Lagergren J. et al . Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.  Ann Intern Med. 2003;  138 176-186
    CrossrefPubMedGoogle Scholar
  • 40 Kearny D J, Crump C, Maynard C, Boyko E J. A case-control study of endoscopy and mortality from adenocarcinoma of the esophagus or gastric cardia in persons with GERD.  Gastrointest Endosc. 2003;  57 823-829
    PubMedGoogle Scholar
  • 41 Breyer H P, de Barros S GS, Maguilnik I, Edelweiss M I. Does methylene blue detect intestinal metaplasia in Barrett’s esophagus?.  Gastrointest Endosc. 2003;  57 505-509
    CrossrefPubMedGoogle Scholar
  • 42 Olliver J R, Wild C P, Sahay P. et al . Chromoendoscopy with methylene blue and associated DNS damage in Barrett’s oesophagus.  Lancet. 2003;  362 373-374
    CrossrefPubMedGoogle Scholar
  • 43 Basu K K, Pick B, Bale R. et al . Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett’s oesophagus: factors determining persistence and recurrence of Barrett’s epithelium.  Gut. 2002;  51 776-780
    CrossrefPubMedGoogle Scholar
  • 44 Morino M, Rebechi F, Giaccone C. et al . Endoscopic ablation of Barrett’s esophagus using argon plasma coagulation (APC) following surgical laparoscopic fundoplication.  Surg Endosc. 2003;  17 539-542
    CrossrefPubMedGoogle Scholar
  • 45 Gurski R R, Peters J H, Ghagen J A. et al . Barrett’s esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features.  J Am Coll Surg. 2003;  196 706-712
    CrossrefPubMedGoogle Scholar
  • 46 Chen L Q, Hu C Y, Der Sarkissian S. et al . Apoptosis in Barrett’s oesophagus following antireflux surgery.  Br J Surg. 2002;  89 1444-1449
    CrossrefPubMedGoogle Scholar
  • 47 Parilla P, Martinez de Haro L F, Ortiz A. et al . Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus.  Ann Surg. 2003;  237 291-298
    CrossrefPubMedGoogle Scholar
  • 48 Corley D A, Kerlekowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis.  Gastroenterology. 2003;  124 47-56
    CrossrefPubMedGoogle Scholar
  • 49 Sonnenberg A, Fennerty M B. Medical decision analysis of chemoprevention against esophageal adenocarcinoma.  Gastroenterology. 2003;  124 1758-1768
    CrossrefPubMedGoogle Scholar
  • 50 Attwood S AE, Lewis C J, Caplan S. et al . Argon plasma coagulation as therapy for high-grade dysplasia in Barrett’s esophagus.  Clin Gastroenterol Hepatol. 2003;  1 258-263
    CrossrefPubMedGoogle Scholar
  • 51 May A, Gossner L, Pech O. et al . Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute phase and intermediate results of a new treatment approach.  Eur J Gastroenterol Hepatol. 2002;  14 1085-1091
    CrossrefPubMedGoogle Scholar
  • 52 Pacifica R J, Wang K K, Wongkeesong L M. et al . Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett’s esophagus.  Clin Gastroenterol Hepatol. 2003;  1 252-257
    CrossrefPubMedGoogle Scholar

H. Koop, M.D.

II. Innere Klinik · HELIOS Klinikum Berlin

Karower Straße 11 · 13122 Berlin · Germany ·

Fax: + 49-30-94 01 42 62

Email: hkoop@berlin.helios-kliniken.de

      >